Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01265433 · ClinicalTrials.gov registry record · Phase 2
Galinpepimut-S (WT-1 Analog Peptide) Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy
A Phase 2 study, sponsored by Sellas Life Sciences Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
NCT01265433 is a Phase 2 study that has completed, run by Sellas Life Sciences Group. The registered enrollment target is 41 participants.
The verdict
NCT01265433, a Phase 2 study, has completed, sponsored by Sellas Life Sciences Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
Study Summary
Study of galinpepimut-S, a Wilms Tumor-1 (WT1) vaccine, to see if it delays or prevents the mesothelioma from growing back after surgery. WT1 is a protein in cancer cells that regulates gene expression and causes cell growth.
Interventions
- BIOLOGICAL Galinpepimut-S + Montanide + GM-CSF
- BIOLOGICAL Montanide + GM-CSF
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2010-12-21 |
| Est. Completion | 2017-07-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01265433
The ClinicalTrials.gov registry entry for NCT01265433 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sellas Life Sciences Group, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Galinpepimut-S + Montanide + GM-CSF is the first listed.
NCT01265433 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01265433 about?
NCT01265433 is a clinical study titled "Galinpepimut-S (WT-1 Analog Peptide) Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy". Study of galinpepimut-S, a Wilms Tumor-1 (WT1) vaccine, to see if it delays or prevents the mesothelioma from growing back after surgery. WT1 is a protein in cancer cells that regulates gene expression and causes cell growth.
What is the current status of trial NCT01265433?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2010-12-21. Estimated completion is 2017-07-25.
What interventions are being tested in trial NCT01265433?
The interventions under investigation include: Galinpepimut-S + Montanide + GM-CSF (BIOLOGICAL), Montanide + GM-CSF (BIOLOGICAL).
Who is sponsoring clinical trial NCT01265433?
This trial is sponsored by Sellas Life Sciences Group, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.